I really hope that our 10-Q will focus on the positive news that I think WE CAN CONTROL. That is, a review of our stellar CMML results, prompting the initiation of a related aGvHD trial, which could lead to a cure for certain myelodysplastic leukemias, with announcement of a share recall of our Outstanding Shares, which I think we own entirely, and the declaration of a 5:1 forward stock split, in preparation of an intended merger, resulting in the re-listing of our stock on the Nasdaq Stock Exchange.